Life Science Risk Assessment
Comprehensive risk assessment across clinical, regulatory, commercial, and technical dimensions. Physician-engineer analysis backed by proprietary data. Results in as fast as 24 hours.
The Process
Three steps from submission to actionable intelligence
Complete a brief intake form about your device, regulatory status, and strategic goals. Takes about 10 minutes. We handle the rest.
Our physician and biomedical engineer conduct independent reviews drawing on federal regulatory data and clinical-technical expertise. Co-review ensures rigorous, multi-disciplinary assessment.
A clear, concise report covering risk classification, strategic positioning, and prioritized next steps — calibrated to your role (founder, investor, acquirer, or TTO).
Your Deliverable
A clear, actionable report calibrated to your role and decision stage
Based on comprehensive multi-category analysis across multiple proprietary assessment domains
A composite Vantage Score with risk classification, contextualized against comparable medical devices with validated methodology.
Analysis across clinical, regulatory, commercial, and technical dimensions — each grounded in verifiable federal data sources.
Your strongest competitive positions and the risk areas requiring attention — prioritized by impact and urgency for your specific situation.
Actionable recommendations tailored to your role — whether you're building, investing, acquiring, or licensing.
Our Approach
Not just data. Physician judgment applied to every assessment.
Every score is reviewed by Dr. Arvind Ravinutala (MD) with clinical context that pure data platforms miss — regulatory nuance, adoption barriers, and reimbursement realities.
Aswini Ravinutala (BME) brings device design, manufacturing quality systems, and technical feasibility analysis to every assessment.
Assessments are grounded in proprietary regulatory data, fully cited in your report with verifiable sources.
A founder gets different recommendations than an investor or acquirer. Your report speaks your language and addresses your specific decision criteria.
Our Users
Anonymized composite case studies showing how Vantage Score informs critical decisions
A VC fund needed rapid assessment of a Phase 2 oral GLP-1 compound. Vantage identified a manufacturing scalability gap in peptide synthesis and a competitive window risk from 3 late-stage competitors. Score flagged the compound's differentiated bioavailability profile as a key strength.
Outcome: Fund negotiated better terms based on the risk-adjusted valuation.
An early-stage diagnostics company needed investor-readiness assessment before Series A. Vantage identified that the CLIA waiver pathway was feasible but reimbursement coding would require a new CPT application. Score highlighted strong clinical evidence from 3 peer-reviewed studies.
Outcome: Founder secured $8M Series A with Vantage Score attached to the data room.
A large device company evaluating an acquisition target in digital health. Vantage identified cybersecurity gaps in the De Novo submission strategy and flagged interoperability risks with legacy EHR systems. Score confirmed strong real-world evidence from 15,000-patient registry.
Outcome: Acquirer proceeded with adjusted offer reflecting remediation costs.
Risk Assessment
Understand the hidden risk exposure in your deal and see how Vantage helps you move faster with confidence.
Pricing
All tiers include data sources, scoring, and benchmarking. Scale based on depth and involvement.
Most customers start here and scale based on their role:
24 hours
Rapid automated screening across 25 risk categories. Perfect for validation and first-pass due diligence.
→ Upgrade to full Score
48 hours
Technology • Portfolio • Founder
Role-specific framing with narrative analysis, risk flags, and 30-minute debrief with physician.
Most Popular
48 hours
IC-ready • Pre-LOI
IC executive summary with competitive benchmarking, deal risk matrix, and market sizing.
→ Full 8–12 page report
48 hours
M&A Acquirers
M&A integration risk, regulatory transfer analysis, and 60-minute strategy session with both founders.
→ 10–15 page report
Scaling Beyond Scores: Need deeper analysis? Scores are your foundation. Your assessment fee credits toward Consulting engagements — where we conduct multi-week deep-dives with 40–70+ page deliverables and full team involvement.
Every Score payment is credited in full toward a deeper engagement.
Standard Scores · $2,500 – $7,500
Investment & M&A Scores · $15,000 + $25,000
Scores are your starting point. Each score delivers an abbreviated, data-driven report framed for your specific role — in 24-48 hours. Need the full picture? Your score fee is credited toward a Consulting engagement, where both founders conduct a multi-week deep-dive with 40-70+ page deliverables.
All scores are abbreviated, data-driven reports — differentiated by client framing, not page count. Full DD reports are consulting deliverables.
| Feature | Quick Score $2.5K |
Technology $7.5K |
Portfolio $7.5K |
Founder $7.5K |
Investor $15K |
Corporate $25K |
|---|---|---|---|---|---|---|
| Turnaround | 24 hrs | 48 hrs | 48 hrs | 48 hrs | 48 hrs | 48 hrs |
| Multi-domain risk scores | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Federal data cross-reference | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Data confidence assessment | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Written narrative analysis | — | Incubator-framed | Incubator-framed | Standard | Detailed | Comprehensive |
| Cited federal data references | — | ✓ | ✓ | ✓ | ✓ | ✓ |
| Prioritized action items | — | ✓ | ✓ | ✓ | ✓ | ✓ |
| Risk flags with severity | — | ✓ | ✓ | ✓ | ✓ | ✓ |
| Physician debrief | — | 30 min | 30 min | 30 min | 30 min | 60 min |
| Competitive benchmarking | — | — | — | — | ✓ | ✓ |
| Investment materiality assessment | — | — | — | — | ✓ | ✓ |
| M&A integration risk | — | — | — | — | — | ✓ |
| Regulatory transfer analysis | — | — | — | — | — | ✓ |
| Client framing | Universal | Incubator / Accelerator | Incubator / Accelerator | Founder | Investor / IC | Acquirer / Full DD |
| Report length | ~2 pages | 5-8 pages | 5-8 pages | 5-8 pages | 8-12 pages | 10-15 pages |
Example
A realistic sample from a de-identified medical device company
Your automated Quick Score brief (markdown, ~2 pages) includes:
Section 1: Composite Score & Risk Classification
proprietary multi-factor risk assessment, RED/YELLOW/GREEN risk flag, confidence bands per category
Section 2: Data Audit Trail & Summary
Data completeness per category, federal database citations, automated scoring methodology
Why Trust Vantage
Covering medical devices, pharmaceuticals, biologics, diagnostics, digital health, therapeutics, and combination products
Clinical perspective from Arvind Ravinutala, MD. Real-world understanding of regulatory workflows, clinical adoption barriers, and investor expectations.
Technical rigor from Aswini Ravinutala, BME. Deep expertise in device design, manufacturing quality systems, and product-market complexity.
Federal databases, regulatory records, clinical evidence, and market intelligence — cross-referenced and cited in every report you receive.
Questions about how we protect your data?
Data Security & Privacy → • Book a 20-Min Discovery Call →Get your Vantage Score in as little as 24 hours. No weeks of waiting. Just clear data, expert analysis, and actionable insights.
Or email arvind@vantagebiomed.com directly